Swedish epilepsy specialist signs deal with UK's CGT Catapult

12 January 2018

CGT Catapult, part of a UK government-led industry-boosting initiative, has entered into a collaboration with Swedish neurological specialist CombiGene, related to epilepsy candidate CG01.

The project is aimed at developing a novel manufacturing process for the gene therapy, allowing CombiGene to progress to commercial GMP production and thereafter clinical trials.

The company has developed a platform which uses gene therapy vectors to deliver a combination of neuropeptide y (NPY) and NPY receptors into brain cells. This has been shown in preclinical studies to inhibit epileptic seizures.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK